Ascendis Pharma A/S (ASND) Scheduled to Post Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) will issue its quarterly earnings data on Thursday, April 25th.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.15) by $0.49. The business had revenue of $148.62 million during the quarter, compared to analysts’ expectations of $97.02 million. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Performance

Shares of Ascendis Pharma A/S stock opened at $144.83 on Wednesday. The company has a 50-day simple moving average of $149.15 and a two-hundred day simple moving average of $125.48. Ascendis Pharma A/S has a 52-week low of $66.03 and a 52-week high of $161.00. The stock has a market capitalization of $8.43 billion, a PE ratio of -15.66 and a beta of 0.50.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on ASND. Wedbush boosted their price objective on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a report on Thursday, February 8th. Morgan Stanley reissued an “equal weight” rating and set a $116.00 price objective on shares of Ascendis Pharma A/S in a report on Monday. JPMorgan Chase & Co. boosted their price objective on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a report on Tuesday, April 2nd. Cantor Fitzgerald reissued an “overweight” rating and set a $173.00 price objective on shares of Ascendis Pharma A/S in a report on Thursday, April 18th. Finally, Wells Fargo & Company boosted their price objective on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the company an “overweight” rating in a report on Friday, March 15th. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.25.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.